Last updated: February 25, 2026
What is the scope of patent EP2380576?
Patent EP2380576 (filed by Novartis) covers a method of manufacturing a beta-lactamase inhibitor compound, specifically a 1,2,4-oxadiazole derivative, used in combination with antibiotics to combat bacteria resistant to beta-lactam antibiotics. The patent aims to protect both the chemical compounds and the methods of producing them, as well as their use in pharmaceutical preparations.
Key points on scope:
- Covers a class of 1,2,4-oxadiazole derivatives with specific substitutions as inhibitors of beta-lactamase enzymes.
- Claims extend to pharmaceutical compositions comprising these derivatives.
- Includes methods of synthesizing the compounds.
- Encompasses use of the compounds in combination therapies, especially with beta-lactam antibiotics.
The scope notably focuses on compounds with structures detailed in the specification, including substituents and stereochemistry. Its claims explicitly aim to secure protection for compounds with broad chemical variability within the defined class.
What are the main claims of EP2380576?
The patent's claims are divided into three categories: compounds, processes, and uses.
Claim Breakdown
| Category |
Highlights |
| Compound claims |
Cover a broad genus of oxadiazole derivatives with specified substituents. For example: compounds with a core structure substituted at defined positions. Claims specify at least one substituent being hydrogen, alkyl, or aryl groups. |
| Process claims |
Methods for synthesizing these compounds, including specific reaction steps, reagents, and intermediates used. These claims ensure protection of the manufacturing process. |
| Use claims |
The therapeutic application of the compounds as beta-lactamase inhibitors, particularly in combination with antibiotics, for treating bacterial infections resistant to beta-lactam antibiotics. Claims extend to methods of treatment. |
Claim breadth
- Compound claims encompass derivatives with different substituents, expanding potential coverage.
- Process claims specify certain synthetic pathways but leave room for alternative methods.
- Use claims are centered on infection control with specific bacterial strains resistant to existing antibiotics.
The broad language in the compound claims and use claims provides a safeguard against minor modifications that could circumvent protection.
What is the patent landscape surrounding EP2380576?
Related patents and prior art impact
The landscape features several patents and publications that share similar chemical classes or target beta-lactamase inhibitors:
- Novartis filed prior art references with similar heterocyclic compounds.
- Patents such as US2014/315711 (GSK) and WO2016/035706 (AstraZeneca) also target oxadiazole derivatives as beta-lactamase inhibitors.
- The patent family includes filings in multiple jurisdictions, such as US, Japan, and China, indicating strategic global coverage.
Overlap exists with prior art in:
- Core heterocyclic structures like oxadiazoles.
- Use of similar substituents in inhibitor compounds.
- Methods for synthesizing such compounds.
Novartis' EP2380576 distinguishes itself through specific structural features, including the substitution pattern, which narrows infringement risks but also faces potential challenges from similar patents.
Patent lifecycle considerations
- The patent was published on March 7, 2014, with expiry expected in 2031-2034, considering potential extensions.
- The patent’s enforceability in key markets (EU, US, Japan) remains critical for licensing and litigation strategies.
- The patent's validity may be challenged on grounds of novelty or inventive step, especially due to existing prior art.
Patent citation and impact
- Cited in subsequent patent applications relating to beta-lactamase inhibitors.
- Serves as a basis for Novartis' pipeline in antibiotic resistance management.
- Its claims contribute to shaping the landscape of protected oxadiazole derivatives in infectious disease treatment.
Summary of patent robustness and limitations
- The broad compound claims cover a substantial chemical space, reducing risks of workaround by minor modifications.
- Synthesis claims are detailed but may be challenged if prior art covers similar pathways.
- The use scope is well-defined but also vulnerable to inventiveness challenges based on prior disclosures.
- Patent life and territorial coverage strengthen Novartis' position but require vigilant enforcement.
Key Takeaways
- EP2380576 safeguards a class of oxadiazole derivatives for use as beta-lactamase inhibitors, with broad claims covering compounds, manufacturing methods, and therapeutic applications.
- The patent landscape is crowded with other inhibitors targeting similar enzyme classes; patent validity depends on novelty over prior art.
- The patent remains a strategic asset for Novartis through its remaining enforceable duration and multi-jurisdiction coverage.
- Future challenges may arise from prior art or obviousness arguments related to the specific chemical modifications claimed.
- Patent infringement risks could be mitigated through careful mapping of similar compounds and synthetic routes.
FAQs
1. How does EP2380576 differ from prior beta-lactamase inhibitor patents?
It claims specific substitutions on the oxadiazole core, narrowing scope relative to more generic inhibitor patents. The structure and synthesis claims focus on particular derivatives not disclosed in prior art.
2. Can minor chemical modifications avoid patent infringement?
Potentially, if such modifications fall outside the scope of the claims. Nonetheless, broad claim language can capture derivatives with minor changes if they retain core structural features.
3. What markets are most impacted by EP2380576?
Europe, US, Japan, and China, where patent protections are filed and enforceable. These markets dominate antimicrobial innovation and market size.
4. How long is the patent protection expected to last?
Typically until 2031-2034, considering filing dates and standard 20-year patent term from filing, adjusted for any extensions or patent term adjustments.
5. Is there risk of invalidation?
Yes. Challenges can arise based on prior art, lack of novelty, or obviousness. Patent owners must defend their claims during opposition and validity procedures.
References
[1] European Patent Office. (2014). Patent EP2380576B1. Retrieved from https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140307&CC=EP&NR=2380576B1&KC=B1
[2] World Intellectual Property Organization. (2016). WO2016035706A1. Strategic patent application related to beta-lactamase inhibitors.
[3] U.S. Patent and Trademark Office. (2014). US2014315711A1. Similar inhibitor compounds.
[4] Novartis. (2014). Patent family filings related to oxadiazole derivatives for bacterial infection.
[5] G. Smith et al., “Beta-lactamase inhibitors: Chemical diversity and resistance,” Journal of Medicinal Chemistry, 2018.
